StockData

Organon vs Viatris

OGN and VTRS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How OGN and VTRS compare

Viatris is the larger company, worth 6.5 times as much as Organon ($23.8B against $3.7B).

Viatris grew revenue faster over the last twelve months (4.4% versus −3.2% for Organon).

Both pay dividends: Organon yields 0.58% and Viatris 2.3%.

Organon scores higher on the StockData Score (7 against 6 for Viatris), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricOGNVTRS
Size and price
Market cap$3.7B$23.8B
Share price$13.90$20.74
Change, 1 year82.4%90.1%
Change, 5 years−55.3%62.7%
Beta (5Y)2.210.32
Employees10K30K
StockData Score
Total score7 (better)6
Valuation score12 (better)
Growth score01 (better)
Performance score2 (better)0
Health score11
Dividend score3 (better)2
Valuation
P/E18.1×–
P/S0.6× (better)1.6×
P/B3.1×–
EV/EBITDA–13.4×
P/FCF5.4× (better)12.2×
FCF yield18.5% (better)8.2%
Fair value$12.33$22.57
Margin of safety−12.8%8.1% (better)
Growth
Revenue growth (TTM)−3.2%4.4% (better)
Revenue growth, 5Y average−0.99%3.7% (better)
Net income growth (TTM)−57.5%–
EPS growth (TTM)−59.9%–
EPS growth, 5Y average−39.0%–
Profitability
Gross margin53.1% (better)34.8%
Operating margin–−0.59%
Net margin3.5%–
FCF margin11.1%13.3% (better)
Return on equity20.3%–
Financial health
Debt / equity7.17–
Net debt / EBITDA–4.59
Interest coverage–−0.2×
Current ratio2.02 (better)1.58
Altman Z-score1.041.21 (better)
Piotroski F-score5–
Dividends and buybacks
Dividend yield0.58%2.3% (better)
Payout ratio9.4%–
Years of dividend growth00
Buyback yield–1.3%
Shareholder yield0.58%3.6% (better)
Ownership
Held by institutions83.3%91.5%
Held by insiders0.47%0.36%
Insider net buying, 12 months−$200K (better)−$1.1M
Superinvestors holding–3
Short interest, % of float7.5%3.1%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.